Pfizer has issued a global recall of Oxbryta, a drug approved for the treatment of sickle cell disease (SCD). Oxbryta, which aimed to improve oxygen transport in red blood cells, offered hope to many individuals suffering from this debilitating condition. However, recent findings have revealed that the drug may pose serious life-threatening risks that outweigh its potential benefits, leading to this swift recall.
Why Is Oxbryta Being Recalled?
In a recent press release, Pfizer announced a global recall of Oxbryta after identifying an imbalance in serious side effects, including vaso-occlusive crises and fatal events, among those using the medication. After reviewing clinical data, Pfizer concluded that the risks associated with Oxbryta outweigh its potential benefits for sickle cell disease patients.
Vaso-occlusive events occur when sickled red blood cells block blood flow, depriving tissues of oxygen. This blockage triggers a dangerous inflammatory response that leads to severe symptoms such as:
- Intense pain in the chest, back, and limbs
- Fever
- Organ failure, including kidney damage
- Increased risk of stroke
Many patients experiencing vaso-occlusive events require hospitalization, and in some cases, the events can be fatal. According to the European Medicines Agency (EMA), a clinical trial involving 236 patients revealed at least eight deaths among Oxbryta users, prompting a global safety review that led Pfizer to withdraw the drug from the market.
What Should Patients Do Next?
Patients currently taking Oxbryta should contact their doctors immediately to discuss alternative treatments. While the recall of Oxbryta is a significant setback for those struggling to manage sickle cell disease, patient safety must always come first. Physicians can provide guidance on next steps and explore available treatment options to manage symptoms without the risks posed by Oxbryta.
What is Oxbryta?
Oxbryta, originally developed by Global Blood Therapeutics (GBT), was approved by the U.S. Food and Drug Administration (FDA) in 2019 as a treatment for sickle cell disease. The drug is designed to improve the function of hemoglobin, the molecule in red blood cells that carries oxygen. By reducing the sickling of red blood cells, Oxbryta sought to alleviate many of the symptoms associated with sickle cell disease, including chronic pain, anemia, and the risk of stroke.
Sickle cell disease is a genetic blood disorder that affects nearly 100,000 individuals in the U.S. alone, with a higher prevalence in individuals of African descent. Prior to Oxbryta, treatment options were limited, making the drug a significant breakthrough for both patients and healthcare providers.
Pfizer’s Acquisition of Oxbryta
In 2022, Pfizer acquired Global Blood Therapeutics in a $5.4 billion deal, expanding its portfolio of rare disease treatments. The acquisition was seen as part of Pfizer’s broader strategy to invest in innovative therapies for conditions with high unmet medical needs, such as sickle cell disease.
With the purchase of GBT, Pfizer took over the production and distribution of Oxbryta, hoping to deliver the benefits of the drug to a larger global market. However, just two years after its approval, concerns began to surface regarding the safety of the medication, eventually leading to the global recall.
Legal Help for Patients Affected by the Oxbryta Recall
At Meyers & Flowers, we are committed to advocating for the rights of individuals harmed by dangerous or defective drugs. When pharmaceutical companies fail to adequately test medications or warn the public of potential risks, patients can suffer severe and life-altering injuries. In cases like the Oxbryta recall, our experienced team of Chicago dangerous drugs attorneys can help hold these companies accountable.
If you or a loved one experienced serious side effects from Oxbryta or any other recalled medication, you may be entitled to compensation for your medical expenses, pain and suffering, and other damages. Our firm has a proven track record of handling complex pharmaceutical litigation, and we stand ready to pursue justice on your behalf.
Why Choose Meyers & Flowers for Drug Recall Litigation?
- Extensive Experience: Our team has successfully represented clients in high-profile cases involving recalled and dangerous medications.
- Dedicated Advocacy: We work tirelessly to ensure our clients receive the compensation and care they deserve.
- No Fees Unless We Win: We operate on a contingency basis, meaning you only pay legal fees if we successfully recover damages for you.
If you have been affected by the Oxbryta recall, don’t wait. Contact Meyers & Flowers today at 630-576-9696 for your free, no obligation case evaluation or click here.